ClinicalTrials.gg

Program

GSK3772701

A development code. Also written as “GSK3772701 600 mg”, “GSK3772701 900 mg” and “GSK3772701 150 mg”.

In GlaxoSmithKline's pipeline, P. falciparum whole cell inhibitor. Its studies are mostly in Malaria, Falciparum, led by GlaxoSmithKline.

Furthest: phase 2, since Apr 16, 20262 company-led studies, 1 open or runningNext primary completion: Oct 8, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline21 open or runningphase 2since Apr 16, 2026Apr 16, 2026Oct 8, 2027phase 2 · NCT07545681
  • Named in GlaxoSmithKline’s own pipeline as GSK3772701, phase 1, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 16, 2026First study: phase 2 study in Malaria, FalciparumFirst studyNCT07545681 · 70 planned · Gabon, Uganda
  2. Jun 19, 2026Phase 1 study in Malaria, FalciparumNCT07670377 · 20 enrolled · United States

Ahead

  1. Oct 8, 2027Primary completion: phase 2 study in Malaria, FalciparumNCT07545681

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“P. falciparum whole cell inhibitor”the company's pipeline, read by Claude · source

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07670377Malaria, Falciparum · United States1CompletedAug 24, 202620
NCT07545681Malaria, Falciparum · Gabon, Uganda2RecruitingOct 8, 202770

How it is read

Names in the registry

  • “GSK3772701 600 mg”, 1 entry
  • “GSK3772701 900 mg”, 1 entry
  • “GSK3772701 150 mg”, 1 entry
  • “GSK3772701 400 mg”, 1 entry
  • “GSK3772701 50 mg”, 1 entry

Codes read as this program: GSK3772701.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.